Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Abivax SA (2X1) Stock Price & Analysis

4 Followers

2X1 Stock Chart & Stats

€83.35€3.15(3.93%)
At close: 5:30 PM GMT+1
€80€90€100€110Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
EUR 81.20 - EUR 83.35
52-Week Range
EUR 60.85 - EUR 137.40
Previous Close
EUR 80.20
Volume
N/A
Average Volume (3M)
748
Market Cap
EUR 7.03B
Enterprise Value
EUR 8.80B
Total Cash (Recent Filing)
EUR 410.68M
Total Debt (Recent Filing)
EUR 1.21M
Price to Earnings (P/E)
―
Beta
0.73
Next Earnings
Dec 14, 2026 (Est.)
EPS Estimate
-0.81
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improved Balance Sheet

Low leverage and sharply higher equity improve near-term financial flexibility, giving Abivax more capacity to fund clinical development and absorb operating volatility. This provides a meaningful buffer even though profitability and cash generation remain weak.

Historical Gross Margin

Near-100% gross margins in 2022–2024 indicate that, when revenue was present, the reported economics were attractive. If commercial revenue returns, this margin profile could support operating leverage, although scale and consistency remain unproven.

Focused Therapeutic Strategy

Concentration on chronic inflammatory diseases gives Abivax a defined therapeutic strategy rather than a broad, unfocused portfolio. A lead program in ulcerative colitis and related indications can support focused clinical execution across a coherent disease area.

Bears Say

Persistent Operating Losses

Large and widening net and operating losses through 2025 show that the current cost base is not covered by operating income. Continued losses can consume the improved equity cushion and make progress dependent on funding rather than internally generated earnings.

Persistent Cash Burn

Negative operating and free cash flow every year from 2020–2025, including approximately -162M of free cash flow in 2025, indicates the business remains far from self-funding. Persistent burn can force external financing and constrain R&D investment.

Unstable Revenue Base

Revenue is small and volatile, falling to zero in 2025 after 2024. This lack of dependable commercial inflow weakens visibility into future earnings and leaves the company reliant on financing while its clinical pipeline is developed.

Abivax SA News

2X1 FAQ

What was Abivax SA’s price range in the past 12 months?
Abivax SA lowest stock price was €60.85 and its highest was €137.40 in the past 12 months.
What is Abivax SA’s market cap?
Abivax SA’s market cap is €7.03B.
When is Abivax SA’s upcoming earnings report date?
Abivax SA’s next earnings report is estimated for Dec 14, 2026 (not yet confirmed), which is in 32 days.
How were Abivax SA’s earnings last quarter?
Abivax SA released its earnings results on Sep 21, 2026. The company reported -€1.47 earnings per share for the quarter, missing the consensus estimate of -€0.801 by -€0.669.
Is Abivax SA overvalued?
According to Wall Street analysts Abivax SA’s price is currently Undervalued.
Does Abivax SA pay dividends?
Abivax SA does not currently pay dividends.
What is Abivax SA’s EPS estimate?
Abivax SA’s EPS estimate is -0.81.
How many shares outstanding does Abivax SA have?
Abivax SA has 87,548,100 shares outstanding.
What happened to Abivax SA’s price movement after its last earnings report?
Abivax SA reported an EPS of -€1.47 in its last earnings report, missing expectations of -€0.801. Following the earnings report the stock price went down -4.643%.
Which hedge fund is a major shareholder of Abivax SA?
Currently, no hedge funds are holding shares in DE:2X1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology